NCT06439381

Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

A Multicenter, Randomized, Continuing Trial to Evaluate the Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal polyps.

Conditions

• Chronic Rhinosinusitis

Interventions

Type	Name	Description
DRUG	300mg/600mg of TQH2722 injection	TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

Timeline

• Start date: 2024-07-16
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2024-06-03
• Last updated: 2026-02-27

Locations

28 sites across 1 country: China